# ImmVirX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immvirx-pty

- Industry: Biotechnology
- Headquarters: Australia
- Website: www.immvirx.com
- Total disclosed funding: $36M
- Latest round: Series B (Jun 4, 2023)
- Investors on record: 6

## About

Based in New Lambton Heights, Australia, and founded in 2019, ImmVirX Pty Ltd operates as a developer of oncolytic viral immunotherapy that utilizes RNA viruses to kill the cancer cells and trigger an immune response from the body to stop tumors from developing. The company was co-founded by Dr. Malcolm McColl and Prof. Darren Shafren and is backed by investors such as Acorn Capital and Karst Peak Capital. In June 2023, ImmVirX Pty Ltd raised AUD 25 million in venture funding from new investor Acorn Capital and OneVentures, and other unspecified investors.


ImmVirX develops proprietary oncolytic RNA viruses which have been bio-selected to have potency and the ability to be replicated to kill target tumor cells and not healthy cells, resulting in the potential generation of specific and adaptive immune responses against cancer.

The company intends to use the June 2023 funding to further develop and increase its market reach.

## Funding rounds

- Series B, Jun 4, 2023, $17M — OneVentures, Acorn Capital
- Series A, Oct 8, 2021, $2.1M — Perpetual Limited, Acorn Capital
- Series A, May 6, 2021, $17M — Perpetual Limited, Karst Peak Capital, Acorn Capital, BNP Paribas, Fifth Estate Asset Management

## Investors

- Perpetual Limited — Series A
- Karst Peak Capital — Series A
- Acorn Capital — Series A, Series B
- BNP Paribas — Series A
- Fifth Estate Asset Management (https://capitalatlas.ai/funds/fifth-estate-asset-management) — Series A
- OneVentures (https://capitalatlas.ai/funds/oneventures) — Series B